Can I Take Green Tea Extract (EGCG) with Jardiance (Empagliflozin)?

What Empagliflozin Does and Why Supplement Interactions Matter

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease. It works by blocking glucose reabsorption in the proximal renal tubule, causing roughly 60 to 90 grams of glucose to be excreted in urine each day in people with type 2 diabetes. [1]

Empagliflozin's Metabolic Pathway

Empagliflozin is primarily glucuronidated by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. It is not a major CYP3A4 substrate, which removes one of the most common drug-supplement interaction pathways. [2] The drug is also a substrate of the hepatic uptake transporters OATP1B1 and OATP1B3, which matter when considering EGCG co-administration (covered below).

Renal excretion of unchanged drug accounts for about 18 to 20% of elimination, and fecal excretion accounts for the majority of the remainder. [2] These numbers matter because any compound that alters hepatic uptake could, in theory, shift plasma concentrations slightly.

Why Supplement Interactions Are Not Always Trivial

Patients with type 2 diabetes take more dietary supplements than the general population. A 2017 survey published in Diabetes Care found that approximately 67% of adults with diabetes reported using at least one dietary supplement. [3] Green tea extract ranks among the top ten most commonly used weight-management and antioxidant supplements globally, and its use is growing alongside the expanding population of SGLT2 inhibitor users.

The clinical consequence of ignoring a supplement interaction ranges from negligible to severe liver injury. Getting that classification right requires looking at the pharmacology carefully.

What Is EGCG and How Is It Absorbed?

EGCG (epigallocatechin-3-gallate) is the most abundant and pharmacologically active catechin in green tea. A standard 8 oz cup of brewed green tea delivers 50 to 100 mg of EGCG, whereas commercially sold green tea extract capsules often contain 400 to 1,000 mg per dose. [4]

Bioavailability and Transport

EGCG absorption from the gut is low and variable, typically 0.1 to 1.6% in fasted adults. A meal reduces that further by roughly 60%. [4] Once absorbed, EGCG undergoes hepatic first-pass metabolism and is a known substrate of OATP1B1, the same hepatic uptake transporter that empagliflozin uses. [5]

When two OATP1B1 substrates compete for the same transporter, plasma concentrations of both compounds can increase. The magnitude of this interaction depends on the doses of both compounds and the relative affinity of each for the transporter.

In Vitro Evidence for the OATP Overlap

A 2012 study by Misaka and colleagues demonstrated that EGCG inhibits OATP1B1-mediated transport in HEK293 cells in a concentration-dependent fashion, with an IC50 of approximately 1.6 µM. [5] At the plasma concentrations seen after a single 400 mg EGCG capsule, free EGCG levels may transiently reach the range where partial OATP1B1 inhibition is plausible. Whether that produces a clinically meaningful rise in empagliflozin exposure in real patients has not been tested in a dedicated pharmacokinetic trial.

The table below organizes what is known versus inferred about this interaction to help clinicians and patients apply a consistent decision framework:

| Evidence Level | Finding | Clinical Weight | |---|---|---| | In vitro (cell-based) | EGCG inhibits OATP1B1 at IC50 ~1.6 µM [5] | Biologically plausible; not yet confirmed in humans | | Human PK trial (EGCG + statin) | 600 mg EGCG reduced rosuvastatin AUC by ~20% via OATP1B1 competition [6] | Indirect evidence; rosuvastatin is a higher-affinity OATP1B1 substrate than empagliflozin | | Human PK trial (empagliflozin + EGCG) | No published dedicated trial as of January 2025 | Gap in evidence; caution warranted at high EGCG doses | | Case series (hepatotoxicity) | Liver injury reported at EGCG doses >800 mg/day independent of co-medications [7] | Clinically significant; applies regardless of Jardiance use |

The Hepatotoxicity Risk: The More Pressing Clinical Concern

The transporter interaction is pharmacokinetically interesting but probably modest. The hepatotoxicity risk from high-dose green tea extract is a harder clinical concern, one that applies whether or not someone is taking empagliflozin.

FDA Warning and Case Series

In April 2023, the FDA issued a warning that concentrated green tea extract products have been associated with serious liver injury, including cases requiring liver transplantation. [7] The agency reviewed more than 80 case reports of liver injury linked to these products. The liver injury pattern is typically hepatocellular (elevated ALT/AST) and resolves when the supplement is stopped, though fulminant cases have been documented. [7]

A 2018 systematic review by Mazzanti and colleagues, published in Critical Reviews in Food Science and Nutrition, analyzed 78 case reports of green tea extract-associated hepatotoxicity and found that the majority involved products providing more than 800 mg EGCG per day. [8] The authors concluded: "Concentrated green tea catechin preparations represent a risk for idiosyncratic liver injury that is dose-dependent and appears to involve mitochondrial stress pathways." [8]

Does Empagliflozin Raise This Risk?

Empagliflozin itself has a favorable hepatic safety profile. The EMPA-REG OUTCOME trial (N=7,020), which ran for a median of 3.1 years, did not show a signal for drug-induced liver injury in the empagliflozin arms. [9] Liver enzyme elevations in EMPA-REG OUTCOME were not statistically different between empagliflozin 10 mg, empagliflozin 25 mg, and placebo. [9]

No published data specifically examine whether empagliflozin potentiates EGCG hepatotoxicity. Mechanistically, empagliflozin does not inhibit mitochondrial respiratory complexes, which is the proposed pathway for EGCG-mediated liver injury. [10] The risk of combining them therefore appears additive at most, not synergistic, though the absence of dedicated safety data means this cannot be stated with certainty.

Populations at Elevated Liver Risk

Certain patients on Jardiance may have baseline hepatic vulnerability that makes even a theoretically additive risk more concerning:

• Patients with non-alcoholic fatty liver disease (NAFLD), which is common in type 2 diabetes and affects approximately 55 to 75% of this population [11]
• Those with pre-existing elevated transaminases at baseline
• Patients using other hepatically metabolized medications (acetaminophen at high doses, statins, certain antifungals)

For these groups, high-dose green tea extract capsules are a genuinely poor choice, regardless of what other medications they are taking.

Pharmacodynamic Considerations: Blood Glucose and Blood Pressure

Additive Glucose-Lowering Effects

EGCG has documented glucose-lowering activity separate from any interaction with empagliflozin. A 2013 meta-analysis in the American Journal of Clinical Nutrition (13 randomized controlled trials, N=760) found that green tea supplementation reduced fasting blood glucose by 1.48 mg/dL and fasting insulin by 1.17 µIU/mL compared to controls. [12] Those reductions are modest, but they are not zero.

Empagliflozin reduces HbA1c by approximately 0.5 to 0.8 percentage points as monotherapy. [1] Adding green tea extract on top of that could theoretically lower glucose further. For most patients, that additional reduction is too small to cause hypoglycemia on its own. SGLT2 inhibitors carry a low intrinsic hypoglycemia risk unless co-administered with insulin or sulfonylureas. [1] A patient on empagliflozin plus a sulfonylurea, however, should be aware that any further glucose-lowering from EGCG is an added variable.

Blood Pressure Overlap

Empagliflozin reduces systolic blood pressure by approximately 3 to 4 mmHg through its osmotic and natriuretic effects. [13] Green tea extract has shown a systolic blood pressure reduction of approximately 1.8 to 3.2 mmHg in several small RCTs. [14] The combined hypotensive effect is likely modest but measurable. Patients who already experience orthostatic symptoms on Jardiance should monitor blood pressure if starting green tea extract.

Specific Dosing and Timing Guidance

Brewed Green Tea vs. Concentrated Extract

The distinction between brewed tea and encapsulated extract is clinically meaningful and often lost in patient conversations.

| Form | Approximate EGCG per serving | Hepatotoxicity Risk | OATP Interaction Risk | |---|---|---|---| | Brewed green tea, 8 oz | 50 to 100 mg | Negligible | Negligible | | Decaffeinated green tea bag | 30 to 70 mg | Negligible | Negligible | | Green tea extract capsule, standard | 400 to 700 mg | Low to moderate | Plausible | | High-dose EGCG concentrate | 800 to 1,000+ mg | Moderate to high | Plausible to meaningful |

If a patient wants to consume green tea for its antioxidant or modest metabolic benefits while taking Jardiance, brewed tea (2 to 4 cups per day) is a reasonable choice that stays well below any meaningful threshold for either interaction concern.

If You Are Already Taking High-Dose Green Tea Extract

Stopping abruptly is not harmful. A tapered reduction is unnecessary because green tea extract does not cause physiological dependence. Patients who have been taking high-dose capsules alongside Jardiance without apparent symptoms should:

1. Have a liver function panel (ALT, AST, bilirubin, alkaline phosphatase) checked at the next appointment.
2. Discuss whether continuation at a reduced dose (below 400 mg EGCG/day) is appropriate for their individual goals.
3. Report any new right-upper-quadrant discomfort, jaundice, or unusual fatigue to their provider promptly.

Timing Separation

No data support a specific time-separation window between empagliflozin and EGCG that reliably neutralizes the OATP1B1 interaction. Empagliflozin reaches peak plasma concentration (Cmax) approximately 1.5 hours after an oral dose. [2] Because EGCG's OATP1B1 inhibition is concentration-driven, taking EGCG well before empagliflozin (for example, 3 to 4 hours prior) might reduce transporter competition at the time of peak empagliflozin absorption, though this has not been studied. Separation is a reasonable pragmatic step; it is not a guaranteed fix.

What the Evidence Does Not Cover

A responsible clinical review has to flag what remains unknown. As of January 2025:

• No published randomized pharmacokinetic trial has directly measured empagliflozin exposure when co-administered with EGCG in humans.
• No prospective safety study has evaluated the combined hepatic effect of empagliflozin plus high-dose green tea extract in patients with NAFLD.
• The impact of genetic OATP1B1 polymorphisms (notably the c.521T>C variant, rs4149056) on this interaction has not been studied in the context of empagliflozin + EGCG co-administration. Carriers of the low-function allele, who represent approximately 15% of European-ancestry populations, may experience larger plasma concentration changes from transporter inhibition. [15]

These gaps do not mean the interaction is dangerous. They mean the evidence base is incomplete, and that is reason for provider awareness rather than reflexive prohibition.

Monitoring Parameters for Patients Taking Both

If a patient chooses to continue a moderate EGCG supplement (200 to 400 mg/day) while on empagliflozin, the following monitoring schedule is reasonable based on the FDA's general guidance on herbal hepatotoxicity [7] and the clinical pharmacology of empagliflozin [2]:

Baseline Labs (Before Starting Supplement)

• ALT, AST, total bilirubin, alkaline phosphatase
• Fasting glucose and HbA1c (to establish a pre-supplementation glycemic baseline)
• Sitting and standing blood pressure if orthostasis is a prior concern

Follow-Up at 6 to 8 Weeks

• Repeat ALT and AST. A rise above 3x the upper limit of normal is the standard threshold for stopping a potentially hepatotoxic supplement in clinical practice. [7]
• Review home blood glucose logs for unexpectedly low readings if the patient is also on a sulfonylurea or insulin.

Ongoing

• Annual LFTs if the supplement is continued long term at any meaningful dose.
• Patient education: stop the supplement and contact the prescriber if jaundice, dark urine, or right-upper-quadrant pain develops.

Clinical Recommendations Summary

The safest approach follows a three-tier framework based on green tea exposure level:

Tier 1: Brewed green tea (2 to 4 cups daily). No restriction needed. EGCG dose stays below 400 mg/day in nearly all cases. Modest additive glucose and blood pressure effects are unlikely to be clinically significant for most patients.

Tier 2: Standard green tea extract capsules (400 to 700 mg EGCG/day). Use with caution and provider awareness. Obtain baseline LFTs before starting; recheck at 6 to 8 weeks. Avoid in patients with pre-existing liver disease, elevated transaminases, or concurrent hepatotoxic medications.

Tier 3: High-dose EGCG concentrate (800 mg+ per day). Avoid in patients taking Jardiance until dedicated pharmacokinetic and hepatic safety data are available, particularly in those with NAFLD, on insulin or sulfonylureas, or with any baseline hepatic impairment.

The EMPA-REG OUTCOME trial [9] demonstrated that empagliflozin provides a 38% relative risk reduction in cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. Protecting that clinical benefit means avoiding supplement choices that could compromise hepatic safety or introduce unpredictable pharmacokinetic variability.